Litcius/Paper detail

Predictive Value of 18F-FDG PET/CT Using Machine Learning for Pathological Response to Neoadjuvant Concurrent Chemoradiotherapy in Patients with Stage III Non-Small Cell Lung Cancer

Jang Yoo, Jae‐Ho Lee, Miju Cheon, Sang‐Keun Woo, Myung‐Ju Ahn, Hong Ryull Pyo, Yong Soo Choi, Joung Ho Han, Joon Young Choi

2022Cancers16 citationsDOIOpen Access PDF

Abstract

We investigated predictions from 18F-FDG PET/CT using machine learning (ML) to assess the neoadjuvant CCRT response of patients with stage III non-small cell lung cancer (NSCLC) and compared them with predictions from conventional PET parameters and from physicians. A retrospective study was conducted of 430 patients. They underwent 18F-FDG PET/CT before initial treatment and after neoadjuvant CCRT followed by curative surgery. We analyzed texture features from segmented tumors and reviewed the pathologic response. The ML model employed a random forest and was used to classify the binary outcome of the pathological complete response (pCR). The predictive accuracy of the ML model for the pCR was 93.4%. The accuracy of predicting pCR using the conventional PET parameters was up to 70.9%, and the accuracy of the physicians’ assessment was 80.5%. The accuracy of the prediction from the ML model was significantly higher than those derived from conventional PET parameters and provided by physicians (p < 0.05). The ML model is useful for predicting pCR after neoadjuvant CCRT, which showed a higher predictive accuracy than those achieved from conventional PET parameters and from physicians.

Topics & Concepts

MedicineStage (stratigraphy)Neoadjuvant therapyLung cancerPathologicalChemoradiotherapyPredictive valueRadiologyRetrospective cohort studyStandardized uptake valueCancerPositron emission tomographyNuclear medicineOncologyInternal medicineBreast cancerPaleontologyBiologyRadiomics and Machine Learning in Medical ImagingLung Cancer Diagnosis and TreatmentMedical Imaging Techniques and Applications
Predictive Value of 18F-FDG PET/CT Using Machine Learning for Pathological Response to Neoadjuvant Concurrent Chemoradiotherapy in Patients with Stage III Non-Small Cell Lung Cancer | Litcius